{"analyses":[{"ciLowerLimit":"1.54","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.47","estimateComment":"Unweighted RRs were estimated using a log-binomial regression model with Wald confidence intervals.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<.0001","paramType":"Risk Ratio (RR)","paramValue":"1.95","statisticalMethod":"Log-binomial regression model"},{"ciLowerLimit":"1.52","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.67","estimateComment":"Unweighted RRs were estimated using a log-binomial regression model with Wald confidence intervals.","groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","pValue":"<.0001","paramType":"Risk Ratio (RR)","paramValue":"2.01","statisticalMethod":"Log-binomial regression model"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.8","upperLimit":"69.6","value":"61.0"},{"groupId":"OG001","lowerLimit":"25.4","upperLimit":"37.7","value":"31.3"},{"groupId":"OG002","lowerLimit":"23.1","upperLimit":"38.2","value":"30.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"233"},{"groupId":"OG002","value":"152"}],"units":"Participants"}],"description":"ORR was the percentage of participants with objective response (OR) per IMWG criteria. For the analysis set of participants from Study C1071003 and COTA, OR was partial response (PR) or better (stringent complete response \\[sCR\\]+complete response \\[CR\\]+very good partial response \\[VGPR\\]+PR). For Study C1071003 and Flatiron Health, OR was PR or better (at least VGPR+PR). sCR: CR \\& normal serum free light chain (sFLC) ratio \\& absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum \\& urine, disappearance of any soft tissue plasmacytoma \\& \\<5% plasma cells in BMA, if measured by sFLC only, preceding criteria + normal sFLC ratio. VGPR: Serum \\& urine M-protein detectable by immunofixation but not on electrophoresis; or \\>=90% reduction in serum \\& urine M-protein level \\<100mg/24h. PR: \\>=50% reduction in serum M-protein \\& reduction in 24h urinary M-protein by \\>=90% or \\<200 mg/24h. Clopper-Pearson two-sided 95% exact confidence intervals were estimated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with TCR MM who initiated elranatamab (PF-06863135) following TCR eligibility in study C1071003 (NCT04649359) were included.","id":"OG000","title":"Study C1071003 Cohort A"},{"description":"Participants with RW TCR MM who initiated standard of care treatment following TCR eligibility between 16-Nov-2015 and 31-Mar-2022 identified from COTA database were included.","id":"OG001","title":"COTA Cohort"},{"description":"Participants with RW TCR MM who initiated standard of care treatment following TCR eligibility between 16-Nov-2015 and 31-Mar-2022 identified from Flatiron Health database were included.","id":"OG002","title":"Flatiron Health Cohort"}],"paramType":"NUMBER","populationDescription":"Eligible participants from study C1071003 (Cohort A) and RW participants identified from COTA and Flatiron Health databases were included.","reportingStatus":"POSTED","timeFrame":"From index date until first documentation of progression, death, or the start of new anticancer therapy (median follow-up of 10.4 months for study C1071003 cohort A, 8.8 months and 7.7 months for COTA and Flatiron Health cohorts)","title":"Objective Response Rate (ORR)-Unweighted Analysis","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}